Colorectal Cancer

Oncology Solutions

The Patient Journey

The global burden of colorectal cancer (CRC) is expected to increase by 60 percent to more than 2.2 million new cases and 1.1 million deaths by 2030.1 Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. While the participation rates in screening are increasing, one quarter of the adults aged 50 to 75 years have never been screened.2 The five-year survival rate for colon cancer found at the local stage is 90 percent, highlighting the benefits of early detection.3

  • SIGNA™ Architect AIR™ Edition

    Our premium 3.0T, 70 cm wide bore MRI system leverages intelligent technology to enable patient-friendly exams with exceptional image quality.

  • Computed Tomography

    Your need for quality patient care at low dose with greater productivity and affordability is more important than ever. That’s why we design CT systems that help...

  • Discovery RT

    Discovery RT is a comprehensive radiation therapy solution that allows you to see all that your CT can see.

  • SIGNA™ PETMR with QuantWorks

    Our fully integrated PET/MR system combines TOF, quantitative accuracy and high sensitivity with our innovative Q.Clear reconstruction.

The latest in Oncology


INSIGHTS
1. Global patterns and trends in colorectal cancer incidence and mortality. Melina Arnold1, Mónica S Sierra1, Mathieu Laversanne1, Isabelle oerjomataram1, Ahmedin Jemal2, Freddie Bray1. Arnold M, et al. Gut 2017;66:683–691. doi:10.1136/gutjnl-2015-310912 683
2. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/colorectal-cancer-screening2?ds=1&s=colorectal cancer
3. https://www.gastroconsa.com/colon-cancer-statistics/

JB04823XX